Neu REFIX Research on Duchenne Muscular Dystrophy to be presented at Muscular Dystrophy Association Conference 2023

GN Corporation will present the results of preclinical and clinical studies with neu REFIX (N-163), one of its Nichi Glucan brand products, in Duchenne muscular dystrophy at the MDA – The Muscular Dystrophy Association – Clinical & Scientific Conference (March 19-22, 2023 in Dallas).

The path-breaking results on the ability of Neu REFIX to aid muscle regeneration and maturation in MDX mice and its clinical efficacy to improve muscle strength in six-month clinical trial including 6MWT, MRC and NSAA will be presented.

Neu REFIX is a beta-glucan food supplement, produced by the N-163 strain of Aureobasidium Pullulans.

Other News

Other articles